Dyax Announces Underwriter’s Exercise of Over-
April 05, 2010 04:20 PM Eastern Daylight Time
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Dyax Corp. (NASDAQ: DYAX) announced today that
Jefferies & Company, Inc. exercised in full its over-allotment option to purchase an additional 2,550,000 shares of
the Company’s common stock at a public offering price of $3.25 per share. The over-allotment option was granted
to the underwriters by Dyax in connection with its recent offering of common stock. The exercise of the option brings
the aggregate net proceeds from the offering to approximately $59.6 million. The sale of the additional shares closed
on April 5, 2010.
Jefferies & Company, Inc. acted as the sole book-running manager of the offering with Needham & Company, LLC
acting as the co-lead manager.
Dyax intends to use the net proceeds from this offering to fund commercialization and distribution activities for
KALBITOR® (ecallantide), its lead product for the treatment of acute attacks for hereditary angioedema, to fund
other research and preclinical development activities, and for general corporate purposes.
A registration statement relating to the shares of Dyax common stock being offered has been filed with, and declared
effective by, the Securities and Exchange Commission (the “SEC”). A final prospectus supplement related to the
offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Copies of the final
prospectus supplement and related prospectus may be obtained from Jefferies & Company, Inc., Attention:
Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022 or at (888) 449-2342. This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such state or j